Abstract:Alzheimer's disease (AD) is a progressive neurological disorder that affects the central nervous system (CNS), leading to memory and cognitive decline. In AD, the brain experiences three main structural changes: a significant decrease in the quantity of neurons, the development of neurofibrillary tangles (NFT) composed of hyperphosphorylated tau protein, and the formation of amyloid beta (Aβ) or senile plaques, which are protein deposits found outside cells and surrounded by dystrophic neurites. Genetic studies have identified four genes associated with autosomal dominant or familial early-onset AD (FAD): amyloid precursor protein (APP), presenilin 1 (PS1), presenilin 2 (PS2), and apolipoprotein E (ApoE). The formation of plaques primarily involves the accumulation of Aβ, which can be influenced by mutations in APP, PS1, PS2, or ApoE genes. Mutations in the APP and presenilin (PS) proteins can cause an increased amyloid β peptides production, especially the further form of amyloidogenic known as Aβ42. Apart from genetic factors, environmental factors such as cytokines and neurotoxins may also have a significant impact on the development and progression of AD by influencing the formation of amyloid plaques and intracellular tangles. Exploring the causes and implications of protein aggregation in the brain could lead to innovative therapeutic approaches. Some promising therapy strategies that have reached the clinical stage include using acetylcholinesterase inhibitors, estrogen, nonsteroidal anti-inflammatory drugs (NSAIDs), antioxidants, and antiapoptotic agents. The most hopeful therapeutic strategies involve inhibiting activity of secretase and preventing the β-amyloid oligomers and fibrils formation, which are associated with the β-amyloid fibrils accumulation in AD. Additionally, immunotherapy development holds promise as a progressive therapeutic approach for treatment of AD. Recently, the two primary categories of brain stimulation techniques that have been studied for the treatment of AD are invasive brain stimulation (IBS) and non-invasive brain stimulation (NIBS). In this article, the amyloid proteins that play a significant role in the AD formation, the mechanism of disease formation as well as new drugs utilized to treat of AD will be reviewed.

Therapeutic Approaches to Alzheimer'S Disease Through Stimulating of Non-Amyloidogenic Processing of Amyloid Precursor Protein

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

The Recent Updates of Therapeutic Approaches Against Aβ for the Treatment of Alzheimer's Disease

Targeting Amyloidogenic Processing of APP in Alzheimer’s Disease

An overview on therapeutics attenuating amyloid β level in Alzheimer's disease: targeting neurotransmission, inflammation, oxidative stress and enhanced cholesterol levels

Proteolytic processing of Alzheimer's β-amyloid precursor protein.

The roles of amyloid precursor protein (APP) in neurogenesis: Implications to pathogenesis and therapy of Alzheimer disease.

Regulation of β cleavage of amyloid precursor protein

Alzheimer's disease: The role of proteins in formation, mechanisms, and new therapeutic approaches

Progress in the Development of Nonpeptidomimetic BACE 1 Inhibitors for Alzheimers Disease

Regulation Of Beta Cleavage Of Amyloid Precursor Protein

The Amyloid-Beta Clearance: From Molecular Targets to Glial and Neural Cells

The Distinct Role of ADAM17 in APP Proteolysis and Microglial Activation Related to Alzheimer’s Disease

Molecular mechanisms in Alzheimer's disease and related potential treatments such as structural target convergence of antibodies and simple organic molecules

Current Updates on the Regulation of Beta-Secretase Movement As a Potential Restorative Focus for Management of Alzheimer's Disease.

Advances in the β-amyloid precursor protein of Alzheimer's disease

Regulation of Alpha-Secretase ADAM10 In vitro and In vivo: Genetic, Epigenetic, and Protein-Based Mechanisms

Secretases Related to Amyloid Precursor Protein Processing

Molecular and cellular mechanisms for Alzheimer's disease: understanding APP metabolism.

Regulation Of Alzheimer'S Disease Amyloid-Beta Formation By Casein Kinase I

Alpha-Secretase ADAM10 Regulation: Insights into Alzheimer’s Disease Treatment